S&P 500   2,971.10 (+0.03%)
DOW   26,854.60 (+0.14%)
QQQ   191.51 (+0.21%)
AAPL   237.48 (+0.54%)
FB   184.11 (-0.04%)
MSFT   139.98 (+0.21%)
CGC   18.98 (-2.32%)
NVDA   185.91 (-0.04%)
BABA   171.73 (-0.71%)
GE   8.75 (-0.57%)
TSLA   255.68 (+3.14%)
T   37.44 (-0.37%)
F   8.81 (+0.34%)
NFLX   283.09 (+0.06%)
BAC   29.12 (+0.73%)
GILD   64.83 (+1.31%)
DIS   129.72 (-0.23%)
S&P 500   2,971.10 (+0.03%)
DOW   26,854.60 (+0.14%)
QQQ   191.51 (+0.21%)
AAPL   237.48 (+0.54%)
FB   184.11 (-0.04%)
MSFT   139.98 (+0.21%)
CGC   18.98 (-2.32%)
NVDA   185.91 (-0.04%)
BABA   171.73 (-0.71%)
GE   8.75 (-0.57%)
TSLA   255.68 (+3.14%)
T   37.44 (-0.37%)
F   8.81 (+0.34%)
NFLX   283.09 (+0.06%)
BAC   29.12 (+0.73%)
GILD   64.83 (+1.31%)
DIS   129.72 (-0.23%)
Log in

Dermira Stock Price, News & Analysis (NASDAQ:DERM)

$5.61
-0.08 (-1.41 %)
(As of 10/14/2019 11:37 AM ET)
Today's Range
$5.48
Now: $5.61
$5.61
50-Day Range
$5.31
MA: $7.59
$9.35
52-Week Range
$5.30
Now: $5.61
$15.48
Volume2,795 shs
Average Volume771,140 shs
Market Capitalization$305.18 million
P/E RatioN/A
Dividend YieldN/A
Beta1.32
Dermira, Inc, a biopharmaceutical company, develops and commercializes therapies for patients with dermatologic diseases in the United States. The company offers QBREXZA, a topical once-daily anticholinergic cloth for the treatment of primary axillary hyperhidrosis in adult and pediatric patients nine years of age and older. It also develops lebrikizumab, a novel injectable humanized monoclonal antibody targeting interleukin 13 that is in Phase IIb clinical trial for the treatment of moderate-to-severe atopic dermatitis; and early-stage research and development programs in other areas of dermatology. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:DERM
CUSIPN/A
Phone650-421-7200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$42.34 million
Book Value($0.21) per share

Profitability

Net Income$-221,540,000.00
Net Margins-306.91%

Miscellaneous

Employees333
Market Cap$305.18 million
Next Earnings Date11/6/2019 (Estimated)
OptionableOptionable

Receive DERM News and Ratings via Email

Sign-up to receive the latest news and ratings for DERM and its competitors with MarketBeat's FREE daily newsletter.


Dermira (NASDAQ:DERM) Frequently Asked Questions

What is Dermira's stock symbol?

Dermira trades on the NASDAQ under the ticker symbol "DERM."

How were Dermira's earnings last quarter?

Dermira Inc (NASDAQ:DERM) announced its quarterly earnings data on Wednesday, August, 7th. The biopharmaceutical company reported ($0.33) earnings per share for the quarter, beating analysts' consensus estimates of ($0.90) by $0.57. The biopharmaceutical company earned $66.65 million during the quarter, compared to the consensus estimate of $34.16 million. Dermira had a negative net margin of 306.91% and a negative return on equity of 478.29%. View Dermira's Earnings History.

When is Dermira's next earnings date?

Dermira is scheduled to release their next quarterly earnings announcement on Wednesday, November 6th 2019. View Earnings Estimates for Dermira.

What price target have analysts set for DERM?

9 brokers have issued 12 month target prices for Dermira's shares. Their forecasts range from $6.71 to $25.00. On average, they expect Dermira's share price to reach $18.71 in the next twelve months. This suggests a possible upside of 230.9% from the stock's current price. View Analyst Price Targets for Dermira.

What is the consensus analysts' recommendation for Dermira?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dermira in the last year. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Dermira.

What are Wall Street analysts saying about Dermira stock?

Here are some recent quotes from research analysts about Dermira stock:
  • 1. According to Zacks Investment Research, "Dermira, Inc. is a specialty biopharmaceutical company. It is focused on bringing medical dermatology products to dermatologists and their patients. The Company markets topical small molecule therapeutics that target acne, sebaceous gland hyperactivity, and inflammatory skin diseases. Its late-stage product candidates comprise Cimzia which has completed Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; DRM04 that is in a Phase IIb clinical trial for the treatment of hyperhidrosis or excessive sweating; and DRM01 which has completed a Phase IIa clinical trial for the treatment of acne. Dermira, Inc. is headquartered in Redwood City, California. " (10/9/2019)
  • 2. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We maintain our Buy rating and $7 price target. The STING program currently contributes approximately 53% to our valuation (no contribution from early stage Lilly program currently) and the APRIL program approximately 43%, with the remainder coming from the anti-CD27 program being developed by Merck (MRK; not rated). Our target is based on our clinical net present value (NPV) model. This model allows us to flex multiple assumptions affecting a drug’s potential commercial profile." (5/8/2019)
  • 3. Cantor Fitzgerald analysts commented, "DERM is a leading dermatology company with commercial and pipeline advancements that could drive upwards earnings revisions and the stock higher. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $25." (5/3/2019)

Has Dermira been receiving favorable news coverage?

Media headlines about DERM stock have been trending negative on Monday, InfoTrie Sentiment reports. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Dermira earned a news sentiment score of -2.6 on InfoTrie's scale. They also gave media coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for Dermira.

Who are some of Dermira's key competitors?

What other stocks do shareholders of Dermira own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Dermira investors own include Exelixis (EXEL), Novavax (NVAX), Gilead Sciences (GILD), Advanced Micro Devices (AMD), Celgene (CELG), Micron Technology (MU), SCYNEXIS (SCYX), Cara Therapeutics (CARA), Inovio Pharmaceuticals (INO) and Karyopharm Therapeutics (KPTI).

Who are Dermira's key executives?

Dermira's management team includes the folowing people:
  • Mr. Thomas G. Wiggans, Co-Founder, CEO & Chairman (Age 67)
  • Dr. Eugene Andrew Bauer, Co-Founder, Chief Medical Officer & Director (Age 77)
  • Mr. Andrew L. Guggenhime, Chief Financial Officer (Age 51)
  • Ms. Lori Lyons-Williams, Chief Commercial Officer (Age 42)
  • Mr. Christopher M. Griffith, Co-Founder and Chief Bus. & Strategy Officer (Age 43)

How do I buy shares of Dermira?

Shares of DERM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Dermira's stock price today?

One share of DERM stock can currently be purchased for approximately $5.66.

How big of a company is Dermira?

Dermira has a market capitalization of $307.63 million and generates $42.34 million in revenue each year. The biopharmaceutical company earns $-221,540,000.00 in net income (profit) each year or ($5.24) on an earnings per share basis. Dermira employs 333 workers across the globe.View Additional Information About Dermira.

What is Dermira's official website?

The official website for Dermira is http://www.dermira.com/.

How can I contact Dermira?

Dermira's mailing address is 275 Middlefield Road Suite150, Menlo Park CA, 94025. The biopharmaceutical company can be reached via phone at 650-421-7200 or via email at [email protected]


MarketBeat Community Rating for Dermira (NASDAQ DERM)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  311 (Vote Outperform)
Underperform Votes:  289 (Vote Underperform)
Total Votes:  600
MarketBeat's community ratings are surveys of what our community members think about Dermira and other stocks. Vote "Outperform" if you believe DERM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DERM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/14/2019 by MarketBeat.com Staff

Featured Article: Elliott Wave Theory

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel